Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics

Advanced Drug Delivery Reviews

Volumn 34, Issue 2-3, 1998, Pages 171-189

  Allémann, Eric ^a   Leroux, Jean Christophe ^b   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

In vivo studies; Microparticles; Nanoparticles; Oral administration; Peptides; Peptidomimetics

Indexed keywords

ABSORPTION; BIODEGRADATION; BIOPOLYMERS; ENCAPSULATION; NANOSTRUCTURED MATERIALS; PARTICLES (PARTICULATE MATTER); PROTEINS;

ORAL ADMINISTRATION; ORAL DELIVERY; PEPTIDES; PEPTIDOMIMETICS;

CONTROLLED DRUG DELIVERY;

NANOPARTICLE; PEPTIDE; PEPTIDOMIMETIC AGENT; POLYMER; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; ENCAPSULATION; GASTROINTESTINAL TRACT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; REVIEW;

EID: 0141830659     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00039-8     Document Type: Review

References (67)

1. Hillery A.M., Toth I., Florence A.T. Co-polymerised peptide particles. II: oral uptake of a novel co-polymeric nanoparticulate delivery system for peptides. J. Control. Release. 42:1996;65-73.
2. A.K. Banga, 1995. Therapeutic Peptides and Proteins. Technomic Publishing Company, Lancaster.
3. Szentkuti L. Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon. J. Control. Release. 46:1997;233-242.
4. Smith M.W., Thomas N.W., Jenkins P.G., Miller N.G.A., Cremaschi D., Porta C. Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. Exp. Physiol. 80:1995;735-743.
5. Jani P., Halbert W., Langridge J., Florence A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42:1990;821-826.
6. Irache J.M., Durrer C., Duchêne D., Ponchel G. Bioadhesion of lectin-latex conjugates to rat intestinal mucosa. Pharm. Res. 13:1996;1716-1719.
7. Florence A.T., Hillery A.M., Hussain N.A., Jani P.U. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Targeting. 3:1995;65-70.
8. Florence A.T., Hillery A.M., Hussain N., Jani P.U. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J. Control. Release. 36:1995;39-46.
9. Desai M.P., Labhasetwar V.D., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13:1996;1838-1845.
10. O'Hagan D.T. The intestinal uptake of particles and the implications for drug and antigen delivery. J. Anat. 189:1996;477-482.
11. Florence A.T. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res. 14:1997;259-266.
12. Allémann E., Gurny R., Doelker E. Drug loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39:1993;173-191.
13. Lowe P.J., Temple C.S. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 46:1994;547-552.
14. Vranckx H., Demoustier M., Deleers M. A new nanocapsule formulation with hydrophilic core: application to the oral administration of salmon calcitonin. Eur. J. Pharm. Biopharm. 42:1996;345-347.
15. H. Vranckx, H.M. Demoustier, M. Deleers, 1996. Pharmaceutical Compositions Containing Nanocapsules. US. Pat. 5,500,224.
16. Leone-Bay A., McInnes C., Wang N., DeMorin F., Achan D., Lercara C., Sarubbi D., Haas S., Press J., Barantsevich E., O'Broin B., Milstein S., Paton D. Microsphere formation in a series of derivatized α-amino acids: properties, molecular modeling, and oral delivery of salmon calcitonin. J. Med. Chem. 38:1995;4257-4262.
17. Milstein S.J., Barantsevich E.N., Grechanovski V.A., Sarubbi D.J. pH-dependent microspheres from modified soybean protein hydrolysate. J. Microencapsulation. 13:1996;651-665.
18. Birrenbach G., Speiser P.P. Polymerized micelles and their use as adjuvants in immunology. J. Pharm. Sci. 65:1976;1763-1766.
19. Al-Khouri Fallouh N., Roblot-Treupel L., Fessi H., Devissaguet J.P., Puisieux F. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int. J. Pharm. 28:1986;125-132.
20. Sarubbi D., Variano B., Haas S., Maher J., Falzarano L., Burnett B., Fuller G., Santiago N., Milstein S., Baughman R.A. Oral delivery of calcitonin in rats and primates using proteinoid microspheres. Proc. Int. Symp. Control. Release Bioact. Mater. 21:1994;288-289.
21. Leone-Bay A., Santiago N., Achan D., Chaudhary K., DeMorin F., Falzarano L., Haas S., Kalbag S., Kaplan D., Leipold H., Lercara C., O'Toole D., Rivera T., Rosado C., Sarubbi D., Vuocolo E., Wang N., Milstein S., Baughman R.A. N-Acylated α-amino acids as novel oral delivery agents for proteins. J. Med. Chem. 38:1995;4263-4269.
22. Bonduelle S., Carrier M., Pimienta C., Benoît J.P., Lenaerts V. Tissue concentration of nanoencapsulated radiolabelled cyclosporin following peroral delivery in mice or ophthalmic applications in rabbits. Eur. J. Pharm. Biopharm. 42:1996;313-319.
23. Bonduelle S., Foucher C., Leroux J.C., Chouinard F., Cadieux C., Lenaerts V. Association of cyclosporin to isohexylcyanoacrylate nanospheres and subsequent release in human plasma in vitro. J. Microencapsulation. 9:1992;173-182.
24. Molpeceres J., Guzman M., Aberturas M.R., Chacon M., Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J. Pharm. Sci. 85:1996;206-213.
25. Chouinard F., Kan F.W.K., Leroux J.C., Foucher C., Lenaerts V. Preparation and purification of polyhexylcyanoacrylate nanocapsules. Int. J. Pharm. 72:1991;211-217.
26. P. Couvreur, M. Roland, P. Speiser, 1982. Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them. US Pat. 4,329,332.
27. Bonduelle S., Pimienta C., Benoît J.P., Lenaerts V. Body distribution in mice of intravenously injected radiolabelled cyclosporin associated with polyisohexylcyanoacrylate nanocapsules or nanospheres. Eur. J. Pharm. Biopharm. 41:1995;27-30.
28. H. Fessi, J.P. Devissaguet, F. Puisieux, C. Thies, 1986. Procédé de préparation de systèmes colloïdaux dispersibles d'une substance, sous forme de nanoparticules. French Pat. 2,608,988.
29. Oppenheim R.C., Stewart N.F., Gordon L., Patel H.M. The production and evaluation of orally administered insulin nanoparticles. Drug Dev. Ind. Pharm. 8:1982;531-546.
30. Damgé C., Michel C., Aprahamian M., Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carriers. Diabetes. 37:1988;246-251.
31. Morishita I., Morishita M., Takayama K., Machida Y., Nagai T. Enteral insulin delivery by microspheres in 3 different formulations using Eudragit L100 and S100. Int. J. Pharm. 91:1993;29-37.
32. Morishita I., Morishita M., Takayama K., Machida Y., Nagai T. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharm. 78:1992;9-16.
33. Morishita M., Morishita I., Takayama K., Machida Y., Nagai T. Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation. Int. J. Pharm. 78:1992;1-7.
34. Michel C., Roques M., Couvreur P., Vranckx H., Baldschmidt P., Damgé C. Isobutyl cyanoacrylate nanoparticles as drug carrier for oral administration of insulin. Proc. Int. Symp. Control. Release Bioact. Mater. 18:1991;97-98.
35. Morishita I., Morishita M., Machida Y., Nagai T. Controlled release microspheres based on Eudragit L100 for the oral administration of erythromycin. Drug Design Delivery. 7:1991;309-319.
36. Damgé C., Hillaire-Buys D., Puech R., Hoeltzel A., Michel C., Ribes G. Effects of orally administered insulin nanocapsules in normal and diabetic dogs. Diabetes Nutr. Metab. 8:1995;3-9.
37. Hillery A.M., Toth I., Shaw A.J., Florence A.T. Co-polymerised particles (CPP). I: synthesis, characterization and in vitro studies on a novel oral nanoparticulate delivery system. J. Control. Release. 41:1996;271-281.
38. Barratt G., Puisieux F., Yu W.P., Foucher C., Fessi H., Devissaguet J.P. Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules. Int. J. Immunopharmacol. 16:1994;457-461.
39. Yu W.P., Barratt G.M., Devissaguet J.P., Puisieux F. Anti-metastatic activity in vivo of MDP-L-alanyl-cholesterol (MTP-chol) entrapped in nanocapsules. Int. J. Immunopharmacol. 13:1991;167-173.
40. Al-Khouri N., Fessi H., Roblot-Treupel L., Devissaguet J.P., Puisieux F. Etude et mise au point d'un procédé original de préparation de nanocapsules de polyalkylcyanoacrylates par polymérisation interfaciale. Pharm. Acta Helv. 61:1986;274-281.
41. Lehr C.M., Bouwstra J.A., Kok W., De Boer A.G., Tukker J.J., Verhoef J.C., Breimer D.D., Junginger H.E. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat. J. Pharm. Pharmacol. 44:1992;402-407.
42. Lehr C.M., Bouwstra J.A., Tukker J.J., Junginger H.E. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat - a comparative study with copolymers and blends based on poly(acrylic acid). J. Control. Release. 13:1990;51-62.
43. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses. 8:1992;153-164.
44. Leroux J.C., Cozens R., Roesel J.L., Galli B., Kubel F., Doelker E., Gurny R. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J. Pharm. Sci. 84:1995;1387-1391.
45. Leroux J.C., Cozens R., Roesel J.L., Galli B., Doelker E., Gurny R. pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs. Pharm. Res. 13:1996;485-487.
46. Allémann E., Leroux J.C., Gurny R., Doelker E. In vitro sustained release properties of drug loaded poly(D,L-lactic acid) nanoparticles produced by a salting-out procedure. Pharm. Res. 10:1993;1732-1737.
47. Deeks S.G., Smith M., Holodniy M., Kahn J.O. HIV-1 protease inhibitors. J. Am. Med. Assoc. 277:1997;145-153.
48. Barry M., Gibbons S., Back D., Mulcahy F. Protease inhibitors in patients with HIV diseases. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32:1997;194-209.
49. Lang M., Roesel J.L. HIV-1 protease inhibitors: development, status, and potential role in the treatment of AIDS. Arch. Pharm. 326:1993;921-924.
50. Abdel-Meguid S.S., Metcalf B.W., Carr T.J., Demarsh P., DesJarlais R.L., Fisher S., Green D.W., Ivanoff L., Lambert D.M., Murthy K.H.M., Petteway S.R. Jr., Pitts W.J., Tomaszek T.A. Jr., Winborne E., Zhao B., Dreyer G.B., Meek T.D. An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis. Biochemistry. 33:1994;11671-11677.
51. Robins T., Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J. Acquired Immune Defic. Syndr. 6:1993;162-170.
52. Alteri E., Bold G., Cozens R., Faessler A., Klimkait T., Lang M., Lazdins J., Poncioni B., Roesel J.L., Schneider P., Walker M., Woods-Cook K. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob. Agents Chemother. 37:1993;2087-2092.
53. Lin J.H., Chen I.W., Vastag K.J., Ostovic D. pH-dependent oral absorption of L-735,524 a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23:1995;730-735.
54. Sugahara M., Kiriyama A., Hamada Y., Kiso Y., Takada K. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of solvent. Biopharm. Drug Dispos. 16:1995;269-277.
55. Maincent P., Le Verge R., Sado P., Couvreur P., Devissaguet J.P. Disposition kinetics and oral bioavailability of vicamine-loaded polyalkyl cyanoacrylate nanoparticles. J. Pharm. Sci. 75:1986;955-958.
56. Damgé C., Aprahamian M., Balboni G., Hoeltzel A., Andrieu V., Devissaguet J.P. Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. Int. J. Pharm. 36:1987;121-125.
57. Beck P.H., Kreuter J., Müller W.E.G., Schatton W. Improved peroral delivery of avarol with polybutylcyanoacrylate nanoparticles. Eur. J. Pharm. Biopharm. 40:1994;134-137.
58. Landry F.B., Bazile D.V., Spenlehauer G., Veillard M., Kreuter J. Influence of coating agents on the degradation of poly(D,L-lactic acid) nanoparticles in model digestive fluids (USP XXII). Stp Pharma Sci. 6:1996;195-202.
59. 14C]poly(DL-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int. J. Pharm. 106:1994;201-211.
60. Beten D.B., Moës A.J. Controlled-release coevaporates of dipyridamole with acrylic polymers. Int. J. Pharm. 103:1994;243-251.
61. Kondo N., Iwao T., Hirai K.I., Fukuda M., Yamanouchi K., Yokoyama K., Miyaji M., Ishihara Y., Kon K., Ogawa Y., Mayumi T. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J. Pharm. Sci. 83:1994;566-570.
62. Kai T., Akiyama Y., Nomura S., Sato M. Oral absorption improvement of poorly soluble drug using solid dispersion technique. Chem. Pharm. Bull. 44:1996;568-571.
63. F. De Jaeghere, J.C. Leroux, E. Allémann, R. Cozens, B. Galli, E. Doelker, R. Gurny, 1997. Evaluation of pH-sensitive nanoparticles for oral delivery of HIV-1 protease inhibitors, Proc. Coll. Drug Carriers 3rd Exp. Meet.
64. Damgé C., Michel C., Aprahamian M., Couvreur P., Devissaguet J.P. Nanocapsules as carriers for oral peptide delivery. J. Control. Release. 13:1990;233-239.
65. Roques M., Damgé C., Michel C., Staedel C., Crémel G., Hubert P. Encapsulation of insulin for oral administration preserves interaction of the hormone with its receptor in vitro. Diabetes. 41:1992;451-456.
66. Roques M., Crémel G., Hubert P. Biological effects of encapsulated insulin on transfected Chinese hamster ovary cells. Diabetologia. 38:1995;180-186.
67. Michel C., Aprahamian M., Defontaine L., Couvreur P., Damgé C. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J. Pharm. Pharmacol. 43:1991;1-5.